Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs)
$114.10
pos +0.79
+0.69%
Today's Range: 111.79 - 114.50 | AMGN Avg Daily Volume: 3,728,200
Last Update: 04/24/14 - 1:26 PM EDT
Volume: 4,023,396
YTD Performance: -0.67%
Open: $114.11
Previous Close: $113.32
52 Week Range: $94.15 - $128.96
Oustanding Shares: 755,007,290
Market Cap: 90,248,933,220
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 7 8 8
Moderate Buy 0 0 0 0
Hold 11 12 12 12
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.22 2.26 2.20 2.20
Latest Dividend: 0.61
Latest Dividend Yield: 1.91%
Dividend Ex-Date: 05/13/14
Price Earnings Ratio: 19.20
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
19.20 18.00 29.23
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-8.32% 0.49% 111.05%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.20 0.24 0.07
Net Income 16.90 0.10 0.03
EPS 20.30 0.40 0.12
Earnings for AMGN:
EBITDA 7.35B
Revenue 18.68B
Average Earnings Estimates
Qtr (06/14) Qtr (09/14) FY (12/14) FY (12/15)
Average Estimate $2.00 $2.17 $8.12 $8.85
Number of Analysts 3 3 3 3
High Estimate $2.06 $2.22 $8.18 $9.23
Low Estimate $1.93 $2.11 $8.05 $8.56
Prior Year $1.88 $1.93 $7.57 $8.12
Growth Rate (Year over Year) 6.56% 12.26% 7.22% 8.99%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bearishAmgen estimates, target cut at Nomura

Apr 23, 2014 | 8:15 AM EDT

Shares of AMGN now seen reaching $129, according to Nomura. Estimates also reduced, as the company lacks visibility with its latest guidance. Neutral rating.

bearishAmgen price target, EPS cut at Jefferies

Apr 23, 2014 | 7:20 AM EDT

AMGN lowered its numbers, Jefferies said. Lower product sales impacted by historical patterns and inventory drawdown. $142 price target and Buy rating. 

bullishAmgen price target raised at Jefferies

Mar 28, 2014 | 8:08 AM EDT

Shares of AMGN reaching $145, Jefferies said. Driven by increased evolocumab sales estimates. $145 price target and Buy rating. 

bullishAmgen estimates, target boosted at Citi

Mar 18, 2014 | 8:05 AM EDT

Shares of AMGN now seen reaching $155, according to Citigroup. Estimates also upped, given the prospects of the company's cholesterol drug, PCSK9. Buy rating. 

By

Roger Arnold

 | Jan 21, 2014 | 6:00 PM EST

What that means for investors and policymakers alike.

By

Ed Ponsi

 | Jan 10, 2014 | 4:07 PM EST
Thanks for spending time with us today and have a great weekend.
By

Robert Lang

 | Dec 29, 2013 | 11:00 AM EST

Take a long, hard look at yourself -- and at the Fed.

By

Jim Cramer

 | Nov 22, 2013 | 11:40 AM EST

These four names are soaring, and I'd jump into all of them, even after their recent runs.

updateCredit Suisse Healthcare Conf.

Nov 13, 2013 | 7:09 AM EST

Credit Suisse Healthcare Conference (Day 3 of 4) - 11/11/13 - 11/14/13 Phoenix, AZ

By

Bret Jensen

 | Oct 29, 2013 | 2:30 PM EDT

The market is richly priced right now, but you can still find bargains.

I'm looking for buy triggers in TSLA on this pullback. The last low is key!

...
Apple tripling the number of China stores over the next two years is a significant move, a...
Deepwater oil drilling company Diamond Offshore (DO) was up $3.63 per share or + 7.4% toda...
We waited a bit on this one but still banked a nice winner. SOLD AAPL MAY 525 CALL AT 41.6...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.